Literature DB >> 23114061

Risk of invasive pneumococcal disease varies by neighbourhood characteristics: implications for prevention policies.

K A Feemster1, Y Li, A R Localio, J Shults, P Edelstein, E Lautenbach, T Smith, J P Metlay.   

Abstract

This study investigates neighbourhood variation in rates of pneumococcal bacteraemia and community-level factors associated with neighbourhood heterogeneity in disease risk. We analysed data from 1416 adult and paediatric cases of pneumococcal bacteraemia collected during 2005-2008 from a population-based hospital surveillance network in metropolitan Philadelphia. Cases were geocoded using residential address to measure disease incidence by neighbourhood and identify potential neighbourhood-level risk factors. Overall incidence of pneumococcal bacteraemia was 36∙8 cases/100,000 population and varied significantly (0-67∙8 cases/100,000 population) in 281 neighbourhoods. Increased disease incidence was associated with higher population density [incidence rate ratio (IRR) 1∙10/10,000 people per mile², 95% confidence interval (CI) 1∙0-1∙19], higher percent black population (per 10% increase) (IRR 1∙07, 95% CI 1∙04-1∙09), population aged ≤5 years (IRR 3∙49, CI 1∙8-5∙18) and population aged ≥65 years (IRR 1∙19, CI 1∙00-1∙38). After adjusting for these characteristics, there was no significant difference in neighbourhood disease rates. This study demonstrates substantial small-area variation in pneumococcal bacteraemia risk that appears to be explained by neighbourhood sociodemographic characteristics. Identifying neighbourhoods with increased disease risk may provide valuable information to optimize implementation of prevention strategies.

Entities:  

Mesh:

Year:  2012        PMID: 23114061      PMCID: PMC3983277          DOI: 10.1017/S095026881200235X

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  39 in total

1.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

Authors:  K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  National, state, and local area vaccination coverage among children aged 19-35 months --- United States, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-09-17       Impact factor: 17.586

3.  Determinants of community-acquired pneumonia in children and young adults in primary care.

Authors:  J Teepe; L Grigoryan; T J M Verheij
Journal:  Eur Respir J       Date:  2010-05       Impact factor: 16.671

4.  Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults.

Authors:  Deron C Burton; Brendan Flannery; Nancy M Bennett; Monica M Farley; Ken Gershman; Lee H Harrison; Ruth Lynfield; Susan Petit; Arthur L Reingold; William Schaffner; Ann Thomas; Brian D Plikaytis; Charles E Rose; Cynthia G Whitney; Anne Schuchat
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

5.  Racial disparities in receipt of influenza and pneumococcus vaccinations among US nursing-home residents.

Authors:  Yue Li; Dana B Mukamel
Journal:  Am J Public Health       Date:  2010-02-10       Impact factor: 9.308

6.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

7.  Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential.

Authors:  David Greenberg; Noga Givon-Lavi; Nitza Newman; Jacob Bar-Ziv; Ron Dagan
Journal:  Pediatr Infect Dis J       Date:  2011-03       Impact factor: 2.129

8.  Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  J Pekka Nuorti; Cynthia G Whitney
Journal:  MMWR Recomm Rep       Date:  2010-12-10

Review 9.  Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.

Authors:  Daniel J Isaacman; E David McIntosh; Ralf R Reinert
Journal:  Int J Infect Dis       Date:  2009-08-22       Impact factor: 3.623

10.  Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study.

Authors:  Stefan Flasche; Albert Jan Van Hoek; Elizabeth Sheasby; Pauline Waight; Nick Andrews; Carmen Sheppard; Robert George; Elizabeth Miller
Journal:  PLoS Med       Date:  2011-04-05       Impact factor: 11.069

View more
  10 in total

Review 1.  Population-based epidemiology and microbiology of community-onset bloodstream infections.

Authors:  Kevin B Laupland; Deirdre L Church
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

2.  Geographic Variation in Hospitalization for Lower Respiratory Tract Infections Across One County.

Authors:  Andrew F Beck; Todd A Florin; Suzanne Campanella; Samir S Shah
Journal:  JAMA Pediatr       Date:  2015-09       Impact factor: 16.193

3.  Socioeconomic Position and the Incidence, Severity, and Clinical Outcomes of Hospitalized Patients With Community-Acquired Pneumonia.

Authors:  Timothy L Wiemken; Ruth M Carrico; Stephen P Furmanek; Brian E Guinn; William A Mattingly; Paula Peyrani; Julio A Ramirez
Journal:  Public Health Rep       Date:  2020-03-31       Impact factor: 2.792

Review 4.  Pneumococcal Capsular Polysaccharide Immunity in the Elderly.

Authors:  Hugh Adler; Daniela M Ferreira; Stephen B Gordon; Jamie Rylance
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

5.  Spatial variation of pneumonia hospitalization risk in Twin Cities metro area, Minnesota.

Authors:  P Y Iroh Tam; B Krzyzanowski; J M Oakes; L Kne; S Manson
Journal:  Epidemiol Infect       Date:  2017-10-17       Impact factor: 4.434

6.  Influence of environmental conditions and pollution on the incidence of Streptococcus pneumoniae infections.

Authors:  José M Sahuquillo-Arce; Elisa Ibáñez-Martínez; Alicia Hernández-Cabezas; Alba Ruiz-Gaitán; Patricia Falomir-Salcedo; Rosario Menéndez; José L López-Hontangas
Journal:  ERJ Open Res       Date:  2017-12-01

7.  NIH support of mobile, imaging, pervasive sensing, social media and location tracking (MISST) research: laying the foundation to examine research ethics in the digital age.

Authors:  Sarah Dunseath; Nadir Weibel; Cinnamon S Bloss; Camille Nebeker
Journal:  NPJ Digit Med       Date:  2018-01-15

Review 8.  Racial Disparities in Incidence of Legionnaires' Disease and Social Determinants of Health: A Narrative Review.

Authors:  Candis M Hunter; Simone W Salandy; Jessica C Smith; Chris Edens; Brian Hubbard
Journal:  Public Health Rep       Date:  2021-06-29       Impact factor: 3.117

9.  Factors Associated with Streptococcal Bacteremia in Diarrheal Children under Five Years of Age and Their Outcome in an Urban Hospital in Bangladesh.

Authors:  Abu Sadat Mohammad Sayeem Bin Shahid; Tahmeed Ahmed; K M Shahunja; Senjuti Kabir; Fahmida Chowdhury; Abu Syeed Golam Faruque; Sumon Kumar Das; Mohammad Habibur Rahman Sarker; Pradip Kumar Bardhan; Mohammod Jobayer Chisti
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240

Review 10.  Role of Inflammatory Risk Factors in the Pathogenesis of Streptococcus pneumoniae.

Authors:  Ifrah Sohail; Sumit Ghosh; Santhosh Mukundan; Susan Zelewski; M Nadeem Khan
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.